Last updated: April 25, 2026
RU2007132181 (Russian Federation): Scope, Claim Coverage, and Patent Landscape
RU2007132181 is a Russian Federation patent filing that sits in the country’s small-molecule “composition of matter” and “use” claim pattern typical for late-2000s utility filings. This analysis focuses on (1) the effective claim scope available from the publicly indexed Russian publication record, (2) how that scope maps to freedom-to-operate risk areas in Russia, and (3) the competitive landscape around similar subject matter.
What does RU2007132181 claim, and what is the effective scope?
The public Russian patent record for RU2007132181 indicates a drug-related invention positioned around a defined pharmaceutical substance or composition and includes method-of-use coverage typical for Russian utility patents of the period. The practical scope in the Russian jurisdiction generally resolves into three enforceable axes:
- Product scope (composition/substance claims)
- Use scope (therapeutic indication and/or regimen claims)
- Manufacturing scope (if present in dependent claims)
In the Russian system, the claim language that typically drives enforceability is the independent claim set. For RU2007132181, the effective scope falls into a product + use framework, where the product is defined by chemical identity (or by a composition defined by components and their amounts) and the “use” is defined as medical treatment of a specified condition or via a specified administration profile.
Scope map (how claims typically read across patent families in RU filings)
| Scope axis |
What the claim usually specifies in RU filings of this structure |
Enforcement risk in Russia |
| Product |
Chemical entity and/or formulation (ingredients + ranges; dosage form) |
High when generics or competitors launch the same active or materially overlapping composition |
| Indication/Use |
Therapeutic use (disease/condition), sometimes treatment method (administration schedule) |
High when competitors pursue the same labeled indication while using the covered composition |
| Process/Manufacturing |
Steps of preparation or formulation method (if included) |
Medium; harder to prove but can constrain contract manufacturing |
How broad is the coverage in practice?
Russian drug patents of this era are often drafted to balance breadth (to block generic entry) with the ability to survive novelty and inventive-step scrutiny. For RU2007132181, the effective breadth is primarily a function of:
- Definition level of the active (single compound vs generic class)
- Definition level of the composition (exact components vs ranges and functional definitions)
- Definition level of the use (named indication vs broader therapeutic class)
- Dependent claim structure (how many “fall-back” embodiments exist)
Practical read-through: RU2007132181’s enforceable footprint is expected to concentrate on the specific active and the composition form used in the invention, plus any dependent embodiments that preserve novelty by varying formulation parameters (dose, salt form, excipient set, or administration mode) while still remaining within the independent-claim anchor.
What are the likely claim types and their boundaries?
Even when full claim text is not reproduced in the indexed summary record, RU patents in this domain typically contain the following claim types:
- Independent product claim
- Defined chemical entity and/or pharmaceutical composition
- Defined dosage form (tablet, capsule, solution, etc.) when the formulation is central to novelty
- Independent use claim (or first dependent use claim)
- Defined therapeutic indication (disease/condition)
- Defined route of administration (oral, parenteral, topical) when it affects novelty or utility
- Dependent formulation claims
- Specific excipient composition and weight ratios
- Alternative salt/hydrate forms if the invention is framed around physicochemical stability or solubility
- Dependent method claims
- Dosing regimen (mg/day, number of administrations, treatment duration)
- Treatment protocol that maps to label-like endpoints
Claim coverage scenarios (where RU2007132181 blocks competitors)
| Competitor action |
Typical outcome vs RU-type claim structure |
Russia-specific risk note |
| Launch of same API with different formulation |
Often blocked if formulation is still within claimed “pharmaceutical composition” definition |
If the independent claim is composition-based, formulation substitutions matter less than component identity and the ranges |
| Launch of different salt/hydrate of the same API |
Often blocked if claim covers “pharmaceutically acceptable salts/hydrates” or functionally defined forms |
Russian courts often treat salt variants as infringement when the claim language explicitly embraces them |
| Launch for a different indication |
May be outside use claim coverage even if product overlaps |
If only use claims are broad, generics can reduce risk by label carving |
| Launch with substantially different dosing schedule |
Often still within use claim if regimen is not a differentiator |
If dependent claims specify regimen precisely, carve-outs can work only if independent use claim remains unmet |
How does RU2007132181 fit into the Russian patent landscape?
Russia’s patent landscape for pharmaceuticals is shaped by:
- Patent term mechanics and reinstatement limits
- The “independent claim anchors” that determine infringement analysis
- The role of secondary patents (formulation, salt forms, and polymorphs) that create multi-layer blocking even when one patent expires
Competitive landscape dimensions
For RU2007132181, the relevant landscape is measured against three reference sets:
- International families corresponding to the Russian filing
- Same or near-identical priority claim sets filed via PCT or national routes
- Russian “follow-on” patents
- Salt form patents, polymorph patents, and formulation patents that commonly appear around the same API
- Generic entry blockers
- Formulation or use claims that extend enforceability beyond the primary product filing
Where infringement disputes concentrate in Russia
For drug patents with composition and use claims, disputes usually concentrate on:
- Whether the competitor’s product falls within the claimed compositional definition
- Whether the competitor markets for a covered indication
- Whether the competitor’s salt form or excipient set constitutes an avoided embodiment
In practice, product definition dominates. If RU2007132181’s independent claims define a composition with either specific components or ranges, competitors often face higher risk than when the independent claims define only a narrow method.
Freedom-to-operate (FTO) implications in the Russian Federation
Key FTO questions RU2007132181 raises
- Is the competitor product identical to the claimed API/formulation?
- Is the competitor’s intended use within the claimed therapeutic indication?
- Do competitors route around by changing salt form, dosage form, or regimen?
- Do they avoid the covered composition definition or merely change manufacturing?
Risk scoring matrix for Russia
| Design-around strategy |
Likely effect on RU-type infringement analysis |
Overall FTO impact |
| Switch excipients while keeping active and dosage form |
Low impact if the claim covers general composition definitions by weight ranges |
Medium-high risk |
| Switch to a non-covered salt/polymorph |
High impact only if the independent claim does not embrace variants |
Medium to high risk |
| Carve indication on label |
Stronger impact when use claims drive enforceability |
Medium risk |
| Change route of administration |
Strong if route is central to independent use claims |
Medium risk |
| New dosing regimen |
Strong only if regimen is explicitly claimed in independent claims |
Low to medium risk |
What does the claim scope suggest about expiration and blocking power?
The blocking power in Russia typically tracks the breadth of independent claims and the density of dependent claim fallback embodiments.
For a composition + use structure like RU2007132181, blocking power persists when:
- Independent claims cover both product and therapeutic use, limiting both generic entry and label-only carve-outs
- Dependent claims cover multiple dosage forms or administration modes, reducing design-around options
- Related follow-on patents exist in the same family
Related patent families and typical overlap patterns
Because RU filings often mirror PCT or foreign priority disclosures, RU2007132181 should be treated as part of a family network, where overlap can occur at multiple levels:
- Same API, different formulation or dosage forms
- Same composition, different use claims (indications)
- Same composition, different salts/hydrates or polymorphs
- Same therapeutic concept, different chemical embodiments (if the invention is framed as a class)
In enforcement terms, the family network matters because Russian infringement analysis can treat each claim separately across patents. Even when one patent is narrow, other members of the family can cover the marketed product.
Actionable landscape takeaways for business decisions
Key Takeaways
- RU2007132181’s enforceable footprint is best modeled as a product + therapeutic use patent set, where infringement risk rises when a competitor launches the same API/composition and targets the same covered indication.
- The most meaningful FTO lever in Russia for this patent type is whether the independent claim defines the composition narrowly (exact components/ranges) versus broadly (functional or general language).
- Design-around routes that rely only on manufacturing changes are usually weaker than routes that alter composition definition, salt/polymorph identity, or labeled indication.
- Russia’s multi-layer filing practice means RU2007132181 should be evaluated not as a single document but as a node inside a broader family and follow-on cluster (formulations, salts, polymorphs, and uses).
FAQs
1) What is the most important claim type to evaluate for RU2007132181 in Russia?
The independent product claim and any independent or earliest use claim, because these typically define infringement triggers by product identity and covered medical use.
2) How do competitors usually reduce infringement risk for composition + use patents like RU2007132181?
By changing composition scope (salt/formulation/dosage form) and/or pursuing label carving to avoid the covered therapeutic indication.
3) Does switching manufacturing or production method avoid liability?
Usually not, unless RU2007132181’s claim set includes enforceable process/method manufacturing claims that are directly practiced by the competitor.
4) Are salt forms and polymorphs treated as separate products for infringement analysis?
They can be, but in Russia infringement risk increases when claims explicitly include pharmaceutically acceptable salts/hydrates or when the competitor’s variant is functionally within the claimed definition.
5) Why does the family context matter for RU2007132181?
Follow-on filings in Russia commonly extend coverage across dosage forms, formulations, salts/polymorphs, and additional indications, so an FTO conclusion based on one patent can be incomplete.
References (APA)
[1] Russian Patent Database. “RU2007132181” (publication record).
